Literature DB >> 11952150

To interfere and to anti-interfere: the interplay between hepatitis C virus and interferon.

Yupeng He1, Michael G Katze.   

Abstract

As popular strategies used by numerous viruses, interception of interferon (IFN) signaling and inhibition of IFN-induced antiviral functions allow viruses to evade the host immune response and set up successful infections. Hepatitis C virus (HCV), the leading cause of chronic liver disease worldwide and a major public health hazard, causes persistent infection in the majority of infected individuals. IFN-based therapies, currently the only ones available for HCV infection, have been unable to eliminate viral infection in the majority of patients, and many studies suggest that HCV possesses mechanisms to antagonize the IFN-induced antiviral response. Multiple viral, host, and IFN-associated factors have been implicated in the interplay between HCV and IFN. Two viral proteins, NS5A and E2, became the focus of much attention and extensive study because of their abilities to inhibit IFN-induced, double-stranded RNA-activated protein kinase (PKR), a major mediator of the IFN-induced biologic response, and to perturb the IFN signaling pathway. In this review, we discuss the significance of the interferon sensitivity determining region (ISDR) within NS5A, which has been the subject of intense debates. In addition, we discuss the potential mechanisms by which NS5A interferes with IFN signaling and the current working models. Further understanding of the molecular mechanisms underlying the interaction between HCV and IFN will likely facilitate improvement of current IFN-based therapies and development of novel treatments for the HCV pandemic. Future HCV research will benefit from both the development of efficient, convenient model systems for viral propagation, and the utilization of high throughput, genomic-scale approaches.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11952150     DOI: 10.1089/088282402317340260

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  29 in total

1.  Inhibition of the protein kinase PKR by the internal ribosome entry site of hepatitis C virus genomic RNA.

Authors:  Jashmin Vyas; Androulla Elia; Michael J Clemens
Journal:  RNA       Date:  2003-07       Impact factor: 4.942

2.  Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91.

Authors:  Yusuke Funaoka; Naoya Sakamoto; Goki Suda; Yasuhiro Itsui; Mina Nakagawa; Sei Kakinuma; Takako Watanabe; Kako Mishima; Mayumi Ueyama; Izumi Onozuka; Sayuri Nitta; Akiko Kitazume; Kei Kiyohashi; Miyako Murakawa; Seishin Azuma; Kiichiro Tsuchiya; Mamoru Watanabe
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

3.  Dissociation of a MAVS/IPS-1/VISA/Cardif-IKKepsilon molecular complex from the mitochondrial outer membrane by hepatitis C virus NS3-4A proteolytic cleavage.

Authors:  Rongtuan Lin; Judith Lacoste; Peyman Nakhaei; Qiang Sun; Long Yang; Suzanne Paz; Peter Wilkinson; Ilkka Julkunen; Damien Vitour; Eliane Meurs; John Hiscott
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  Morphine withdrawal enhances hepatitis C virus replicon expression.

Authors:  Chuan-Qing Wang; Yuan Li; Steven D Douglas; Xu Wang; David S Metzger; Ting Zhang; Wen-Zhe Ho
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

5.  Negative regulation of intracellular hepatitis C virus replication by interferon regulatory factor 3.

Authors:  Tsuyoshi Yamashiro; Naoya Sakamoto; Masayuki Kurosaki; Nobuhiko Kanazawa; Yoko Tanabe; Mina Nakagawa; Cheng-Hsin Chen; Yasuhiro Itsui; Tomoyuki Koyama; Yoshie Takeda; Shinya Maekawa; Nobuyuki Enomoto; Hiroshi Sakugawa; Mamoru Watanabe
Journal:  J Gastroenterol       Date:  2006-08       Impact factor: 7.527

6.  ISG56 and IFITM1 proteins inhibit hepatitis C virus replication.

Authors:  Amit Raychoudhuri; Shubham Shrivastava; Robert Steele; Hangeun Kim; Ranjit Ray; Ratna B Ray
Journal:  J Virol       Date:  2011-10-05       Impact factor: 5.103

Review 7.  Viral hepatitis: new data on hepatitis C infection.

Authors:  Erzsébet Szabó; Gábor Lotz; Csilla Páska; András Kiss; Zsuzsa Schaff
Journal:  Pathol Oncol Res       Date:  2003-12-22       Impact factor: 3.201

8.  Hepatitis C virus impairs TLR3 signaling and inhibits IFN-λ 1 expression in human hepatoma cell line.

Authors:  Yizhong Wang; Jieliang Li; Xu Wang; Li Ye; Yu Zhou; Rebecca M Thomas; Wenzhe Ho
Journal:  Innate Immun       Date:  2013-03-25       Impact factor: 2.680

9.  SH2 modified STAT1 induces HLA-I expression and improves IFN-γ signaling in IFN-α resistant HCV replicon cells.

Authors:  Bret Poat; Sidhartha Hazari; Partha K Chandra; Feyza Gunduz; Luis A Balart; Xavier Alvarez; Srikanta Dash
Journal:  PLoS One       Date:  2010-09-30       Impact factor: 3.240

10.  Predictive factors for interferon and ribavirin combination therapy in patients with chronic hepatitis C.

Authors:  Joonho Yoon; Jong In Lee; Soon Koo Baik; Kwang Ho Lee; Joon Hyung Sohn; Hyean Woo Lee; Jun Namkung; Sei Jin Chang; Jong Whan Choi; Hyun Won Kim; Byung-Il Yeh
Journal:  World J Gastroenterol       Date:  2007-12-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.